ClinicalTrials.gg
RecruitingNCT05845333Updated Nov 13, 2026

Neurocognitive Abnormalities in Stimulant Abuse Among High-Risk Women

An observational study in Stimulant Abuse and Criminal Behavior, sponsored by The Mind Research Network. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by The Mind Research Network · Observational

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
334
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Criminal Behavior with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Criminal Behavior · United States.

Started
2022
with 1 other
Observational
Only one
of the 22
Registered
19th of 22
by date
Lead sponsor
2 of 22
The Mind Research Network

Among the 22 studies in Criminal Behavior with a site in United States, this one is one of 2 that started in 2022, is the only observational one, and was the 19th registered.

Criminal Behavior

29 studies on the registry are indexed under Criminal Behavior; 8 are open to participants now.

Browse Criminal Behavior studies →

Open to participants now

4 of the 22 studies in Criminal Behavior with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Criminal Behavior studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Criminal Behavior with a site in United States, or all of them as a file.
02

Study summary

Substance use disorders and psychopathy are serious and costly mental health issues. Psychopathy is known to be associated with aberrant moral decision making and there is considerable interest in determining whether substance use disorders lead to impairments in these same cognitive processes. Recent large-scale research initiatives in forensic settings have begun to identify substance abuse and psychopathy-related disruption in the neural mechanisms involved in moral decision-making processes, and associations between these neural networks and future relapse and antisocial behavior. Here the investigators extend prior work (with incarcerated men) to examine these issues among incarcerated women in order to better understand sex differences. This project addresses the overall lack of neurocognitive research in criminal offenders with substance use disorders, thereby focusing on a major public health issue in an underserved and understudied population.

Read the detailed description

There continues to be great interest and public health relevance with regard to understanding the neurobiological systems that underlie the comorbidity of substance use disorders and other psychiatric conditions. In a previous award, efforts were focused upon characterizing the neural circuitry underlying moral decision making in incarcerated men with varying levels of two frequently co-occurring conditions: stimulant abuse and psychopathy. Here this work will be extended to incarcerated women, to examine longitudinal outcomes and apply state-of-the-art network analyses for predictive models. Prior studies have demonstrated sex differences in the degree and expression of psychopathic traits, patterns of stimulant abuse, and moral decision-making. However, the neural circuitry that underlies these sex differences is not well understood. Substantial sex differences in regional gray matter volume and density in extant samples have also been identified. Collectively, sex differences in pathophysiology could have significant implications for treatment strategies and differential biomarkers of treatment prediction and outcome in men and women. The investigators will implement the research strategy with a large incarcerated population by deploying a unique mobile MRI scanner to the regional women's prison. Participants will be stratified by level of lifetime stimulant (cocaine, amphetamine) use severity and psychopathic traits (high, medium, low) and will undergo anatomical and functional MRI scanning while completing multi-modal (i.e., linguistic and picture) decision-making tasks. Results will be compared to those obtained in a prior award (incarcerated men, n>300). Functional network and dynamic network connectivity will also be examined in women using a new multiband echo planar imaging (EPI) pulse sequence, and longitudinal outcomes after release to the community will be collected to test behavioral and neuropredictive models of relapse and future antisocial behavior. This work is expected to generate a large, robust dataset that characterizes the overlapping and unique aspects of neural circuitry underlying stimulant use and psychopathy in females and males. The proposed research is in line with recent priorities emphasized by the National Institute on Drug Abuse (NIDA) for projects aimed at examining male-female differences, and effects specific to females, to improve understanding of the nature and etiology of drug abuse.

03

Conditions studied

  • Stimulant Abuse
  • Criminal Behavior

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Incarcerated and non-incarcerated adult women

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biological sex is female
  • Intelligence Quotient 70 or higher
  • Reading level 5th grade or higher
  • Able to speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Uncorrectable auditory or visual deficits
  • Currently pregnant
  • MRI
  • Central nervous system disease
  • Current major medical condition
  • Hypertension with complications (e.g., stroke)
  • Diabetes with complications
  • Lifetime history of psychotic disorder
  • Self-report of psychotic disorder (with psychiatric hospitalization) in first degree relative
  • Drug use in past three months

(Healthy controls only):

  • History of arrest
  • Substance use beyond light alcohol or marijuana use
  • Currently taking psychotropic medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
334 participants (estimated)
Patient registry
No

Groups and cohorts

  • Stimulant Use Severity High

    Other: Decision task

  • Stimulant Use Severity Medium

    Other: Decision task

  • Stimulant Use Severity Low

    Other: Decision task

  • Psychopathic Traits High

    Other: Decision task

  • Psychopathic Traits Medium

    Other: Decision task

  • Psychopathic Traits Low

    Other: Decision task

  • Community (Healthy) Controls

    Other: Decision task

Interventions

  • OtherDecision task

    Participants will complete a simple and/or moral decision making functional MRI task.

06

What researchers measure

Primary outcomes

  1. Gray matter volume during MRI scan & stimulant use

    Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  2. White matter integrity during MRI scan & stimulant use

    White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  3. Functional brain response during MRI scan & stimulant use during simple linguistic decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  4. Functional brain response during MRI scan & stimulant use during simple picture decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  5. Functional brain response during MRI scan & stimulant use during moral linguistic decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  6. Functional brain response during MRI scan & stimulant use during moral picture decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  7. Functional connectivity during MRI scan & stimulant use during simple linguistic decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  8. Functional connectivity during MRI scan & stimulant use during simple picture decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  9. Functional connectivity during MRI scan & stimulant use during moral linguistic decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  10. Functional connectivity during MRI scan & stimulant use during moral picture decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with stimulant use (assessed using a modified version of the Addiction Severity Index)

    Time frame: During MRI procedure

  11. Gray matter volume during MRI scan & psychopathic traits

    Gray matter volume (using relevant MRI analysis platforms - Statistical Parametric Mapping/SPM) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  12. White matter integrity during MRI scan & psychopathic traits

    White matter integrity (using relevant MRI analysis platforms - Functional Magnetic Resonance Imaging of the Brain software library (FSL)) correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  13. Functional brain response during MRI scan & psychopathic traits during simple linguistic decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  14. Functional brain response during MRI scan & psychopathic traits during simple picture decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  15. Functional brain response during MRI scan & psychopathic traits during moral linguistic decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  16. Functional brain response during MRI scan & psychopathic traits during moral picture decision task

    Functional brain responses (Blood Oxygen Level Dependent/BOLD) (using relevant MRI analysis platforms - SPM, Group Independent Components Analysis Functional Toolbox/GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  17. Functional connectivity during MRI scan & psychopathic traits during simple linguistic decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Simple Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  18. Functional connectivity during MRI scan & psychopathic traits during simple picture decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT)) during Simple Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  19. Functional connectivity during MRI scan & psychopathic traits during moral linguistic decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Linguistic Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  20. Functional connectivity during MRI scan & psychopathic traits during moral picture decision task

    Functional connectivity (using relevant analysis MRI platforms - GIFT) during Moral Picture Decision Task correlation with psychopathic traits (assessed using the Psychopathy Checklist-Revised)

    Time frame: During MRI procedure

  21. Relapse to/change in stimulant use post-release

    Return to stimulant use (assessed using timeline follow back calendar (TLFB)) post-release from incarceration

    Time frame: Every 3 months post release for duration of grant (5 years)

  22. Return to/change in antisocial behavior post-release

    Return to antisocial behavior (assessed via self report and/or official records) post-release from incarceration

    Time frame: Every 3 months post release for duration of grant (5 years)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for May 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
May 6, 2023
StartActual
Aug 1, 2022
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05845333
Lead sponsor
The Mind Research Network
Responsible party
Kent Kiehl (Professor of Psychology, Neuroscience and Law, Executive Science Officer, The Mind Research Network) — Principal investigator
First posted
May 6, 2023
Start date
Aug 1, 2022
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Carla Harenski
Contact
charenski@mrn.org
505-272-5028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion